NASDAQ: RNTX
Rein Therapeutics Inc Stock

$1.71-0.07 (-3.93%)
Updated Apr 30, 2025
RNTX Price
$1.71
Fair Value Price
$0.72
Market Cap
$37.61M
52 Week Low
$1.35
52 Week High
$4.40
P/E
-0.49x
P/B
0.69x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$62.88M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$22M
Beta
1.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

RNTX Overview

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine RNTX's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
RNTX
Ranked
Unranked of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important RNTX news, forecast changes, insider trades & much more!

RNTX News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RNTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RNTX ($1.71) is overvalued by 138.44% relative to our estimate of its Fair Value price of $0.72 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RNTX ($1.71) is not significantly undervalued (138.44%) relative to our estimate of its Fair Value price of $0.72 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RNTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RNTX due diligence checks available for Premium users.

Valuation

RNTX fair value

Fair Value of RNTX stock based on Discounted Cash Flow (DCF)

Price
$1.71
Fair Value
$0.72
Overvalued by
138.44%
RNTX ($1.71) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RNTX ($1.71) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RNTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RNTX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.49x
Industry
-162.28x
Market
29.18x

RNTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.69x
Industry
4.45x
RNTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RNTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$41.0M
Profit Margin
0%
RNTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$62.2M
Liabilities
$7.8M
Debt to equity
0.14
RNTX's short-term assets ($13.66M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RNTX's short-term assets ($13.66M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RNTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RNTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.8M
Investing
$0.0
Financing
$1.0k
RNTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RNTX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
RNTX$37.61M-3.93%-0.49x0.69x
ANTX$37.32M+1.64%-0.72x0.46x
LTRND$37.96M+0.86%-1.82x1.79x
ATHE$36.82M-0.29%-2.78x7.52x
SPRO$36.78M-1.94%-0.52x0.80x

Rein Therapeutics Stock FAQ

What is Rein Therapeutics's quote symbol?

(NASDAQ: RNTX) Rein Therapeutics trades on the NASDAQ under the ticker symbol RNTX. Rein Therapeutics stock quotes can also be displayed as NASDAQ: RNTX.

If you're new to stock investing, here's how to buy Rein Therapeutics stock.

What is the 52 week high and low for Rein Therapeutics (NASDAQ: RNTX)?

(NASDAQ: RNTX) Rein Therapeutics's 52-week high was $4.40, and its 52-week low was $1.35. It is currently -61.14% from its 52-week high and 26.67% from its 52-week low.

How much is Rein Therapeutics stock worth today?

(NASDAQ: RNTX) Rein Therapeutics currently has 21,992,387 outstanding shares. With Rein Therapeutics stock trading at $1.71 per share, the total value of Rein Therapeutics stock (market capitalization) is $37.61M.

Rein Therapeutics stock was originally listed at a price of $216.00 in Jun 29, 2017. If you had invested in Rein Therapeutics stock at $216.00, your return over the last 7 years would have been -99.21%, for an annualized return of -49.91% (not including any dividends or dividend reinvestments).

How much is Rein Therapeutics's stock price per share?

(NASDAQ: RNTX) Rein Therapeutics stock price per share is $1.71 today (as of Apr 30, 2025).

What is Rein Therapeutics's Market Cap?

(NASDAQ: RNTX) Rein Therapeutics's market cap is $37.61M, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Rein Therapeutics's market cap is calculated by multiplying RNTX's current stock price of $1.71 by RNTX's total outstanding shares of 21,992,387.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.